In summary, METTL3-mediated m6A modifications of TRIM11 promoted its transcript stability via the m6A-IGF2BP2-dependent pathway, which may at least partially increase the expression of TRIM11 in drug-resistant NPC cells. The gene discussed is METTL3; the disease is nasopharyngeal carcinoma.